MiNK Therapeutics annual free cash flow
2020
2021
2022
2023
MiNK Therapeutics Free Cash Flow (FCF) History (INKT)
MiNK Therapeutics reported −$15.8M in free cash flow for fiscal 2023, an increase of $3.3M from the previous fiscal year.
View full MiNK Therapeutics company overviewMiNK Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-12-31 | −$15.8M | $3.3M | — | — |
| 2022 | 2022-12-31 | −$19.1M | −$6.0M | — | — |
| 2021 | 2021-12-31 | −$13.1M | −$4.6M | — | — |
| 2020 | 2020-12-31 | −$8.4M | — | — | — |
MiNK Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$3.0M | $2.6M | — | — |
| Q3 2023 | 2023-09-30 | −$4.2M | −$2.5M | — | — |
| Q2 2023 | 2023-06-30 | −$4.2M | −$580,275 | — | — |
| Q1 2023 | 2023-03-31 | −$4.4M | −$861,776 | — | — |
| Q3 2022 | 2022-09-30 | −$5.7M | −$1.4M | — | — |
| Q4 2021 | 2021-12-31 | −$1.7M | — | — | — |
| Q3 2021 | 2021-09-30 | −$3.6M | — | — | — |
| Q2 2021 | 2021-06-30 | −$3.5M | — | — | — |
| Q1 2021 | 2021-03-31 | −$4.2M | — | — | — |
MiNK Therapeutics free cash flow growth trends
MiNK Therapeutics's latest reported quarter, Q4 2023, generated −$3.0M in free cash flow, an increase of $2.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review MiNK Therapeutics filings at SEC.gov ↗